CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 146,590	$ 105,948
Short-term investments	436,796	289,707
Research and development incentives receivable	2,939	3,055
Prepaid expenses and other current assets	6,278	5,267
Total current assets	592,603	403,977
Property, plant and equipment, net	7,479	7,933
Restricted cash	1,636	1,636
Right-to-use asset – operating leases	5,208	5,552
Right-to-use asset – financing leases	39,665	42,094
Total assets	646,591	461,192
Current liabilities:
Accounts payable	5,364	3,732
Accrued expenses and other current liabilities	24,704	13,392
Operating lease liabilities, current	1,118	1,070
Financing lease liabilities, current	2,639	2,562
Total current liabilities	33,825	20,756
Operating lease liabilities, non-current	4,389	4,801
Financing lease liabilities, non-current	23,965	24,406
Long term debt, net of discount	28,648	0
Other liabilities, non-current	472	0
Total liabilities	91,299	49,963
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2023 and March 31, 2022; 56,676,313 and 47,338,660 shares issued and outstanding as of March 31, 2023 and March 31, 2022, respectively	57	47
Additional paid-in capital	1,034,994	723,359
Accumulated deficit	(485,488)	(311,204)
Accumulated other comprehensive income (loss)	5,729	(973)
Total stockholders’ equity	555,292	411,229
Total liabilities and stockholders’ equity	$ 646,591	$ 461,192